Gilead’s Magrolimab Ineffective, Linked to Increase Risk of Death in MDS Patients

Published: Jun 17, 2024 By Tristan Manalac

Gilead HQ/iStock, Sundry Photography
Pictured: Signage outside Gilead’s headquarters in California/iStock, Sundry Photography

Gilead Sciences on Friday unveiled its final analysis of the Phase III ENHANCE study, providing more details surrounding the troubled development of its blood cancer therapy magrolimab.

In the late-stage trial—which compared magrolimab against placebo in nearly 540 higher-risk myelodysplastic syndromes (HR-MDS) patients who were also receiving standard-of-care azacitidine—Gilead’s antibody resulted in an approximately 20% higher risk of death versus placebo, though this effect was not statistically significant.

Overall survival in the magrolimab arm was also shorter by approximately three months.

Magrolimab’s objective response rate was 53.7%, which was lower than the observed rate of 58.7% in placebo comparators. Median progression-free survival was also slightly shorter in magrolimab-treated patients.

In addition to missing its efficacy endpoints, magrolimab was…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks